Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Freeline Therapeutics Holdings plc (FRLN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.8900+0.0413 (+4.87%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.8487
Open0.8373
Bid0.8602 x 900
Ask0.9094 x 800
Day's Range0.8373 - 0.9300
52 Week Range0.6500 - 15.4000
Volume38,401
Avg. Volume191,267
Market Cap31.875M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.0260
Earnings DateNov 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
  • GlobeNewswire

    Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress

    LONDON, June 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and important clinical data for its AAVS3-based gene therapy candidate FLT180a at the International Society on Thrombosis and Haemostasis (ISTH) Congress to be held in London, July 9-13, 2022. The presentation will provide safety and initial efficacy data from the first cohort of the Phase 1/2 B-LIEVE trial, which aims to confirm the FLT180a dose and immune

  • GlobeNewswire

    Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B

    Initial cohort one data suggest predictable and sustained Factor IX normalization, supporting additional dosing at the same low dose with the same optimized, prophylactic immune management regimen Cohort one efficacy and safety data to be presented at ISTH Congress in July Start-up activities for pivotal Phase 3 trial on track to begin in H1 2023 LONDON, June 14, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it has begun dosing the second cohort

  • GlobeNewswire

    Freeline Announces May 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on May 31, 2022, the Company granted its newly hired Chief Financial Officer, Paul Schneider, and six other newly hired employees non-statutory options to purchase an aggregate of 270,000 and 191,850 of the Company’s ordinary shares, respectively. The awards were granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq List

Advertisement
Advertisement